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Advances in Global Measles Control and Elimination: 
Summary of the 1997 International Meeting
SUMMARY
A meeting concerning advances in measles control and elimination, the third
in a series, was held in Atlanta during August 1997. The meeting was cospon-
sored by CDC, the Pan American Health Organization, the World Health
Organization, and the United Nations Children’s Fund. Meeting participants con-
cluded that substantial progress has been made toward controlling measles.
Measles transmission has been interrupted in several countries, reinforcing the
view that measles eradication is technically feasible using existing vaccines and
intervention strategies. However, measles still accounts for 10% of global mor-
tality from all causes among children aged <5 years ( i.e., approximately
1 million deaths annually). Progress toward measles control varies substantially
among countries and regions. Intensified efforts are necessary to implement
appropriate control and elimination strategies, including supplementary vacci-
nation campaigns, expansion of routine vaccination services, and surveillance.
These strategies and estimates of the resources required to implement them will
require adjustment based on accumulating experience. Programmatic and fi-
nancial obstacles must be overcome if the final goal of measles eradication is to
be achieved.
INTRODUCTION
The Third Meeting on Advances in Measles Control and Elimination was held in
Atlanta from August 27 through 29, 1997. The meeting was cosponsored by CDC, the
Pan American Health Organization (PAHO), the World Health Organization (WHO), and
the United Nations Children’s Fund (UNICEF). The objectives of the meeting were to
• review experience in measles control and elimination at global, regional, and na-
tional levels; 
• discuss present and future priorities for technical, programmatic, and laboratory
support of measles control and elimination;
• review technical and programmatic issues in measles control, particularly mea-
sles surveillance, laboratory methods for confirmation of suspected cases,
isolation and typing of measles viruses, vaccine and injection safety, and the
phasing of measles control and elimination activities with polio eradication and
other activities of WHO’s Expanded Programme on Immunization (EPI);
• present findings of cost-benefit analyses of global measles control strategies (in-
cluding eradication) and discuss the use of these findings to develop political and
financial support; and
• improve coordination and cooperation among partners in measles control and
elimination.
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This report, which summarizes the discussions and conclusions of the meeting,
should be read in conjunction with the report of the Second Meeting on Advances in
Measles Control and Elimination (1 ), which concluded,“Participants agreed that mea-
sles eradication is technically feasible with available vaccines and recommended
adoption of the goal of global eradication with a target date during 2005–2010, with
the proviso that measles eradication efforts should not interfere with polio eradication
but should build on the successes of the global Poliomyelitis Eradication Initiative.”
GLOBAL EXPERIENCE WITH MEASLES CONTROL
The efforts of individual countries and global efforts through the EPI have substan-
tially reduced measles morbidity and mortality throughout the world. Worldwide, for
1996, global coverage of the population of children aged 1 year with one dose of mea-
sles vaccine is estimated at 81% (2 ) (Figure 1). However, progress in controlling
measles varies substantially among WHO regions (Figure 2). An estimated 36.5 mil-
lion cases and 1 million deaths caused by measles still occur each year. About half of
these deaths occur in Africa. Sixteen of 19 countries in which fewer than 50% of chil-
dren aged 1 year have received at least one dose of measles vaccine are in Africa.
Despite poor measles surveillance, Africa also has the highest reported incidence of
measles.
Measles Elimination in the Western Hemisphere
In September 1994, the member nations of PAHO established the goal of eliminat-
ing measles from the Western Hemisphere by 2000. The strategy adopted included
three complementary approaches to immunization:
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FIGURE 1. Reported number of measles cases and vaccination coverage* —
worldwide, 1983–1996
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• “Catch-up”: a one-time-only mass campaign to vaccinate all children aged
9 months to 14 years, without regard to disease or vaccination history;
• “Keep-up”: routine vaccination with measles, measles-rubella (MR), or measles-
mumps-rubella (MMR) vaccine at age 12 months; and
• “Follow-up”: periodic campaigns conducted approximately every 4 years to
vaccinate all children aged 1–4 years, without regard to disease or vaccination
history.
Application of this strategy has substantially reduced measles transmission in the
Americas (Figure 3).
Several countries including Chile, Cuba, and the nations of the English-speaking
Caribbean have reported no cases of measles for ≥3 years. In other countries of the
region, measles transmission is now occurring only sporadically. During 1996,
2,109 confirmed cases of measles were reported in the Western Hemisphere—
the fewest ever reported. Of these cases, 44% were confirmed by laboratory tests or
epidemiologically linked to laboratory-confirmed cases, and 56% were classified as
“clinically confirmed” (i.e., neither confirmed by serologic test nor epidemiologically
linked to a serologically confirmed case). Of the laboratory-confirmed cases,
816 (88%) occurred in the United States and Canada. Most countries in the region re-
ported sporadic cases or no cases of measles.
Obstacles to measles elimination in the Americas include increasing numbers of
infants and children who are susceptible to measles, the circulation of measles virus
in other parts of the world, and importation of cases of measles and subsequent
spread of measles virus. The number of infants and children susceptible to measles in
a population tends to increase over time even when high routine vaccination coverage
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with a highly effective vaccine is maintained. For example, in a population with an
annual birth cohort of 100,000 children, 90% routine vaccination coverage, and 90%
vaccine efficacy, approximately 19,000 children are added each year to the population
that is susceptible to measles.
The state of São Paulo, Brazil experienced an outbreak of measles during 1997. By
the end of December, >31,000 cases had been reported. This outbreak occurred after
several years during which few measles cases occurred because of a catch-up mea-
sles vaccination campaign in 1987 and a campaign conducted during 1992 to
vaccinate children aged 1–10 years with MMR vaccine. After the 1992 campaign,
health authorities in São Paulo state implemented a two-dose measles vaccination
strategy. The first dose is routinely administered to infants aged 9 months and the
second dose to children aged 15 months. During the 1997 outbreak, most cases oc-
curred among residents of metropolitan São Paulo. During the 1997 outbreak, most
cases occurred among residents of metropolitan Sao Paulo. Provisonal data concern-
ing the age and vaccination status of cases indicate that 64% occurred among persons
aged ≥15 years, most of whom were unvaccinated; 16% occurred among infants and
6% among children aged 1–4 years, many of whom also were unvaccinated. The high-
est age-specific incidence rates were observed among infants (849 cases per 100,000
population), followed by persons aged 20–29 years (307 cases per 100,000 population)
and children aged 1–4 years (91 cases per 100,000 population). The outbreak spread to
other states in Brazil and other countries in the Western Hemisphere.
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FIGURE 3. Reported measles cases — region of the Americas, 1980–1997*†
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Factors contributing to the outbreak in São Paulo have not been completely clari-
fied but may include 
• the aggregation of susceptible young adults, many of whom had migrated to
metropolitan São Paulo from impoverished rural areas;
• the high population density of metropolitan São Paulo; and 
• the presence of many preschool-aged children who were susceptible to measles
because of the low first-dose coverage achieved by routine vaccination services
and the absence of follow-up campaigns.
Genomic sequencing of virus strains isolated from persons with measles in São Paulo
during 1997 revealed that these strains were identical or nearly identical to viruses
circulating in parts of Europe, indicating that the outbreak may have been triggered by
importation of measles virus from Europe.
In Canada, introduction of measles vaccine in 1963 substantially reduced the occur-
rence of measles. The country relied on a one-dose measles vaccination strategy until
1995, when a major outbreak (i.e., >2,000 cases) prompted adoption of a two-dose
vaccination schedule. The second dose is administered to children aged 18 months or
4–5 years. The two-dose strategy was implemented in all 12 Canadian provinces dur-
ing 1996 and early 1997. Canada’s National Advisory Committee on Immunization
further recommended that all children and adolescents who had previously received a
single dose of measles-containing vaccine receive a second dose. Six provinces com-
pleted catch-up vaccination of school children in 1996, achieving 90% coverage.
However, during January through April 1997, a measles outbreak occurred in British
Columbia and spread to Alberta. British Columbia had carried out catch-up vaccina-
tion in 1996, achieving 75% coverage of preschool-aged children and approximately
90% coverage of school-aged children. The outbreak in British Columbia primarily in-
volved young adults (i.e., college students) who were not vaccinated during the 1996
catch-up effort. Alberta had not carried out catch-up vaccination and its outbreak,
which occurred from February through July 1997, primarily involved school-aged
children.
In the United States, measles incidence is at the lowest level ever measured. In
1996, a total of 488 cases was reported and, in 1997, a total of 135 cases. International
importations and cases directly linked to international importations accounted for
more than half of all cases reported in 1996 and 1997. During 1996, the reported inci-
dence of measles in the United States was <1 per 1 million population in all age
groups. Measles vaccination coverage among children aged 2 years reached 91% in
1996, and 98% of children entering school had received at least one dose of measles-
containing vaccine. Approximately 64% of all school-aged children had received
two doses of measles vaccine. Evidence from case investigations and molecular
epidemiologic studies indicates that measles transmission has been interrupted in the
United States at least three times—in late 1993, in 1995, and in 1996. During 1992–
1996, Japan, Germany, the Philippines, the United Kingdom, France, India, and Italy
were the leading sources of measles cases imported to the United States. In 1997,
leading exporters of measles cases to the United States were Germany, Italy, Brazil,
China, France, Pakistan, and the Philippines (Figure 4). The increasing proportion of all
measles cases caused by imported virus strains indicates that further reduction of
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measles incidence in the United States requires international cooperation and im-
proved global control of measles.
Other Global Experiences with Measles Control and
Elimination
Africa
In South Africa, measles vaccine was added to the National Immunization Days
(NIDs) for polio eradication in 1996. During 1997, efforts were made to ensure that all
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children aged 1–14 years had received measles vaccine during catch-up vaccination
campaigns in 1996 or 1997. Analysis of South Africa’s experience during the 1996 NIDs
revealed several issues to be addressed in future NIDs in which multiple vaccines are
administered (i.e., training personnel to administer injections, disposing appropriately
of used needles and syringes, and dealing with different target age groups for the two
vaccines). The combined 1996 and 1997 campaigns achieved 91% coverage of the eli-
gible age cohort, although coverage varied substantially among provinces and within
provinces. South Africa is moving to eliminate measles, but accomplishing the goal
will require strengthening surveillance, improving routine vaccination services, and
conducting follow-up campaigns.
Several other countries in southern Africa that have made substantial progress in
polio eradication, and which have strong basic EPI programs (i.e., Namibia, Botswana,
Zimbabwe, and Swaziland), also have launched or are planning catch-up measles vac-
cination campaigns. These countries have not yet established laboratory-based
surveillance.
Western Pacific Region
The Western Pacific Region of WHO includes the most populous as well as some of
the smallest countries of the world. Most countries in the region are now free of polio
and are devoting more attention to measles. Approximately 100,000 cases of measles
are reported in the region each year, despite measles vaccine coverage exceeding
90%. Many countries of the region are now implementing supplemental measles con-
trol activities. During 1996, Mongolia conducted a catch-up campaign to vaccinate
children aged 9 months through 11 years, achieving 97% coverage. Few cases of mea-
sles were reported in Mongolia from July through December 1996, and no confirmed
cases were reported from January through May 1997.
Many of the Pacific island nations have been free of measles for some time, al-
though periodic outbreaks caused by measles importations continue to occur. The
number and size of these outbreaks have decreased steadily since the introduction of
measles vaccination in the mid-1970s. The 20 island nations of Melanesia, Polynesia,
and Micronesia are planning intensified measles control efforts. Through coordinated
action, these nations hope to emulate the successful measles elimination efforts of the
English-speaking Caribbean islands. No measles cases were reported in these 20 na-
tions during 1995, but four outbreaks—all in Polynesia—occurred in 1996.
Other countries in the Western Pacific Region (e.g., Australia, New Zealand, and the
Philippines), have already begun measles elimination initiatives or are considering
them. Nationally, New Zealand has achieved 87% coverage with one dose of measles-
containing vaccine, but in some segments of the population, coverage is substantially
lower. A mass vaccination campaign was planned in July 1997 to prevent an antici-
pated epidemic in these populations, but onset of the epidemic began in April. The
mass campaign was started in May and probably limited spread of measles.
China, which implemented a two-dose measles vaccination schedule in 1985, expe-
rienced substantial reductions in measles morbidity and mortality beginning in 1987.
Fewer than 75,000 cases were reported in 1996, and only 108 deaths were reported in
1995 compared with more than 1 million cases and 4,200 deaths in 1981. In 1997,
China issued a national plan for accelerated measles control. The national plan called
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for the development of provincial plans of action but did not establish a formal na-
tional target date for measles elimination.
Eastern Mediterranean Region
In October 1996, participants in a Consultation on Measles Control/Elimination in
the Eastern Mediterranean Region recommended that enhanced control measures be
undertaken with the aim of eliminating measles from the region. However, partici-
pants also recognized that substantial differences existed among the countries of the
region in vaccination strategies, vaccination coverage, sensitivity of surveillance, and
occurrence of disease. Eight of the 23 countries in the region use a one-dose measles
vaccination strategy; in the 15 that use a two-dose strategy, the age at which the sec-
ond dose is administered and the vaccine of choice (measles vaccine or combination
vaccines [MR or MMR]) vary. In 1996, region-wide coverage of children aged 2 years
with at least one dose of measles-containing vaccine was ≥80% but varied consider-
ably. In two countries, vaccination coverage among children aged 2 years was <50%.
A proposed plan and target date for elimination of measles from the region by
2010 was approved by the WHO Regional Committee in October 1997. The Gulf Coun-
cil countries (i.e., Kuwait, Oman, Bahrain, Qatar, Saudi Arabia, and United Arab
Emirates) are aiming for measles elimination by 2000.
During NIDs conducted during a 1994 cease-fire in Sudan’s ongoing civil conflict,
measles vaccine was administered to 61% of children aged <5 years. During a similar
1995 “Tranquility Days” cease-fire, vaccination for polio, measles, and other diseases
and other public health interventions (i.e., Vitamin A distribution and Guinea worm
eradication activities) were also conducted in war-affected areas. Coverage with mea-
sles vaccine in Sudan is now approximately 75%, and ten of 26 states have measles
vaccination coverage >80%. Coverage in war-affected areas is much lower (<30%). As
a result of special efforts to immunize war-displaced children, substantially fewer out-
breaks of measles have occurred in refugee camps.
European Region
A strategic plan for elimination of measles from the WHO European Region by
2007 has been developed by the WHO European Advisory Group and will be pre-
sented to the WHO European Regional Committee for consideration during 1998. A
questionnaire regarding measles control practices and strategies was sent to all
50 member states; 41 responded. In the 38 responding countries that use a two-dose
measles vaccination strategy, the age for administration of the second dose ranges
from 3 to 14 years. Twenty-one countries in the region report ≥90% coverage with at
least one dose of measles, eight report coverage of 80%–89%, nine indicate 50%–79%
coverage, and three countries report coverage <50%. Regionwide, coverage of chil-
dren aged 12–24 months with at least one dose of measles-containing vaccine is 82%.
The regional strategy to eliminate measles includes: establishing political commit-
ment to measles elimination, developing measles elimination plans based on local
epidemiologic data, achieving and maintaining high vaccination coverage, and
strengthening surveillance. On the basis of their progress in measles control,
European countries have been classified into three groups. Group 1 comprises six
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countries that are close to eliminating the disease. These countries are characterized
by;
• national reporting of suspected cases;
• laboratory testing of a high proportion of sporadic cases (at least one case tested
per 100,000 population per year) and fewer than 10% of suspected cases con-
firmed for the past 5 years; and
• ≥95% measles vaccination coverage for the past 5 years or low prevalence of
susceptibility to measles demonstrated by findings of serologic surveys.
The four countries in Group 2 have achieved good control of measles but are con-
sidered potentially at risk for measles outbreaks. These countries are characterized by
• national reporting of suspected cases; 
• laboratory resources for confirmation of cases; 
• ≥90% measles vaccination coverage for the past 5 years; and 
• stable incidence of reported measles for the past 5 years or an interepidemic
period ≥5 years.
Countries in Group 3 (31 countries ) have poor control of measles and are charac-
terized by 
• <90% (or unknown) measles vaccination coverage; or
• no national reporting of suspected cases; or
• an interepidemic period <5 years.
UNICEF Urban Measles Control Initiative
UNICEF, in collaboration with WHO, is supporting an initiative to reduce deaths
among young children (i.e., those aged <5 years) through urban measles control. The
initiative is intended to catalyze improvements in child health activities in under-
served urban areas. In such areas, where a substantial percentage of children is
susceptible to the disease, measles circulates easily, affects infants, and is often ex-
ported to surrounding rural areas. The UNICEF/WHO strategy is to develop local
partnerships to improve routine immunization services in poor urban areas, plan and
carry out measles campaigns in high-risk areas, develop community-based measles
surveillance, and promote child health and development. The proposed target age
group is children aged 9–59 months, although the age group may vary on the basis of
local epidemiologic findings. In addition to measles vaccination, campaigns under-
taken as part of the initiative will include vitamin A supplementation. Vaccine will be
administered with autodestruct syringes, and safety boxes will be provided for dis-
posal of used injection equipment. Development of measles surveillance to evaluate
the impact of immunization activities will be an integral part of the initiative.
Vol. 47 / No. RR-11 MMWR 9
Conclusions: Progress Toward Measles Elimination
• In countries where they have been fully implemented, the strategies adopted to
eliminate measles (i.e., catch-up, keep-up, and follow-up) in the Western Hemi-
sphere have substantially reduced or eliminated measles. The absence of a
follow-up vaccination campaign, in addition to low routine vaccination coverage,
may have contributed to the outbreak of measles in the state of São Paulo, Brazil
in 1997. However, factors not directly related to implementation of the measles
control strategy (e.g., in-migration of susceptible young adults from rural areas,
high population density, and independent adult transmission) may also have in-
fluenced the course of the outbreak. Analysis of the São Paulo experience
supports the idea that elimination strategies are unlikely to succeed if they are
not implemented completely throughout a country or region.
• Maintenance of high routine vaccination coverage and community-based
surveillance (i.e., case identification, reporting, and investigation) require ade-
quately trained and equipped primary health-care personnel. Strengthening the
primary health-care system and EPI in developing countries, although perhaps
not essential for interruption of measles virus transmission, greatly facilitates
achieving and maintaining measles elimination in a country or region.
• In some countries (particularly in the Americas and the United Kingdom), most
measles cases are now caused by international importations. Consequently,
eliminating measles from these countries requires improvements in measles
control in other parts of the world. In the United States, most virus importations
originate from Europe and Japan, indicating that developed countries, as well as
developing nations, need to improve measles control. Countries can help
improve international communication about areas where measles virus is circu-
lating by notifying their respective WHO regional offices about measles impor-
tations. Such communication can help national health authorities strengthen sur-
veillance and undertake appropriate remedial actions.
• Immunization strategies designed specifically to improve measles control and
reduce measles deaths in densely populated urban areas of low-income coun-
tries should be developed and supported by national governments, WHO, and
UNICEF. These strategies should be directed to vaccinating populations not
covered by routine vaccination services or previous catch-up vaccination cam-
paigns. When supplementary vaccination campaigns are conducted in such
high-risk urban areas, all children in the target age range should be vaccinated
regardless of measles vaccination status or history of previous measles disease.
Disease surveillance is essential to monitor the impact of supplementary vacci-
nation activities and should be developed as part of these strategies.
• Combining measles vaccination campaigns with other public health interven-
tions (i.e., administration of oral poliovirus vaccine or non-vaccine interventions
such as vitamin A supplementation) should be encouraged. However, no single
combination of interventions is appropriate in all circumstances; the combination
of interventions must be specific to the needs and capacities of countries where
they are implemented. For example, countries that can afford combination
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vaccines should consider using MR vaccine or MMR vaccine. Simultaneous ad-
ministration of yellow fever vaccine could also be considered in countries at risk
for yellow fever.
MEASLES SURVEILLANCE 
In a measles elimination program, surveillance is intended to detect measles virus
circulation in a timely manner (rather than to detect every single case), allowing public
health authorities to undertake rapid ascertainment and investigation of suspected
cases, determine risk factors for the disease, and implement outbreak control meas-
ures.
In Latin America and the English-speaking Caribbean, measles surveillance has
been integrated with polio surveillance. Twenty thousand reporting units, at least one
in each district or municipio (equivalent to a township or county), have been estab-
lished in these countries. Weekly reporting is the norm, both for the occurrence of
cases and the absence of cases (i.e., negative reporting). Cases are classified as “sus-
pected,” “discarded,” or “confirmed.” A suspected case is any illness that a health-
care worker suspects might be caused by measles infection. Surveillance norms call
for all suspected cases to be investigated thoroughly and promptly. Thorough investi-
gation includes collection of a single serum specimen at the time of the patient’s first
contact with the health-care system and collection of appropriate specimens for virus
isolation from every detected chain of transmission. A suspected case may be con-
firmed by a positive immunoglobulin M (IgM) antibody test of the serum specimen or
by epidemiologic linkage to a case confirmed by such a laboratory test. Specimens are
tested first with a commercial indirect IgM assay. Specimens that yield indeterminate
results are tested with an IgM-capture enzyme immunoassay (EIA) developed by CDC
(3 ) and are classified as confirmed if this more specific assay yields a positive result.
A suspected case is discarded if a complete investigation fails to identify an
epidemiologic link to a laboratory- confirmed case and a negative result is obtained
from the IgM antibody test of the blood specimen. Suspected cases that are not com-
pletely investigated are classified as “clinically confirmed” and are considered to
represent a failure of the surveillance system. During 1996, in the countries of Latin
America and the Caribbean, a total of 10,144 suspected measles cases was completely
investigated; laboratory tests in 90 (0.9%) cases were positive for measles.
Six surveillance indicators are being used in the Americas as of September, 1997:
• percent of surveillance sites reporting weekly;
• percent of reporting sites that report at least one suspected measles case per
year;
• percent of suspected cases investigated within 48 hours of report;
• percent of suspected cases with adequate blood samples or epidemiologic link-
age to a laboratory-confirmed case;
• percent of outbreaks with known source of infection; and
• percent of blood specimens with results reported within 7 days of receipt in the
diagnostic laboratory.
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During 1995–1997, PAHO conducted evaluations of surveillance systems in Brazil,
El Salvador, Mexico, Nicaragua, Panama, and Venezuela. The evaluations included
interviews with health workers; search of patient records at hospitals, health centers,
schools, day care centers, and private clinics; and analysis of the indicators listed
previously. The reviews concluded that surveillance systems in three of the countries
had the capacity to detect cases rapidly but that surveillance systems in the other
three did not. On the basis of these evaluations, PAHO concluded that its surveillance
indicators were useful for continually monitoring the quality of the regional and na-
tional surveillance systems. PAHO recommended that every member country conduct
periodic evaluations to ensure that its surveillance system is capable of timely detec-
tion of measles virus circulation.
Susceptibility profiles (i.e., estimates of the proportion of the population suscepti-
ble to measles by age) can be useful to help guide measles elimination strategies.
In countries where measles virus continues to circulate, susceptibility profiles can
be developed based on history of vaccination—whether with one or two doses of
measles-containing vaccine—or history of disease, age distribution, and vaccination
status of recent cases. As incidence declines, serologic surveys and mathematical
modeling can be used to estimate susceptibility profiles. These profiles can, in turn, be
used in deciding the timing of and age range for vaccination campaigns. Repeated
serologic surveys are most useful if the incidence of measles is low and the quality of
vaccination coverage data is poor.
Role of the Laboratory in Measles Surveillance
Recent field experience has demonstrated the usefulness and reliability of IgM EIAs
for confirmation of suspected measles cases. Commercially available IgM EIAs can be
done quickly, are sensitive and specific, and require only one serum specimen. The
CDC antibody-capture EIA is used as a confirmatory test after initial testing with one
of the commercially available assays, which are usually simpler and faster to perform
(3). In tests of persons naturally infected with measles virus, the CDC test was positive
in 77% of specimens obtained within 72 hours of rash onset and 100% of specimens
obtained 4–11 days after rash onset; for 90% of these patients, second specimens ob-
tained 28 days after rash onset were also IgM-positive (4 ).
The measles virus is a negative-stranded RNA virus with 15,894 nucleotides and
six genes. Virus isolation and genotyping can be used to monitor changes in the geno-
typic pattern over time if genotyping is done before and after major control and
elimination efforts. These molecular epidemiologic studies can be used to demon-
strate interruption of measles virus transmission when it occurs. To facilitate
communication among laboratories, a standard system of nomenclature to categorize
the genotypes should be developed. In the interim, eight arbitrarily numbered geno-
types—all of them isolated in North America during the period 1988–1997—have been
identified. Group 1 includes all vaccine viruses regardless of geographic origin, sev-
eral recently isolated wild viruses, and all wild viruses isolated from Europe and the
United States during the 1950s and 1960s. Measles viruses isolated in Japan are
mostly from Groups 2 and 3; viruses isolated in Europe are predominantly Groups 4
and 5. Group 6 viruses predominate in Africa and Group 8 in China and Vietnam.
Group 7 viruses have a broad geographic distribution. The resurgence of measles in
12 MMWR July 24, 1998
the United States during 1988–1992 was caused almost entirely by Group 2 viruses.
The absence of Group 2 virus from United States since 1993, except in one case im-
ported from the Philippines, indicates that measles transmission was interrupted in
the United States in 1993.
Conclusions: Measles Surveillance
Epidemiologic Aspects
• The disease burden of measles must be better documented by strengthening
measles surveillance systems, both in developing and developed countries.
• Measles surveillance is an integral part of all efforts to control and eliminate
the disease. The functions and requirements of a surveillance system must
evolve as measles control progresses toward elimination of the disease. In coun-
tries and regions where control of the disease is the goal, surveillance should
indicate patterns of transmission and identify areas or subpopulations where in-
tensified vaccination activities are needed. As control of the disease is achieved
and outbreak prevention or interruption of transmission become the goals of the
program, the surveillance system should develop the capacity to a) detect mea-
sles virus circulation promptly, b) investigate outbreaks thoroughly to ascertain
risk factors for measles, and c) identify areas or subpopulations where program
failures may have occurred. Careful analysis of surveillance data, including find-
ings of outbreak investigations, is needed to make decisions about control
measures and to adjust programmatic strategies.
• In developing a surveillance system, simplicity in case investigation procedures
is desireable, but should not be achieved at the expense of core data elements.
The need for detailed data about each case evolves in parallel with programmatic
progress toward elimination.
• Training is important to help workers know when and what to report. A case may
enter the surveillance system either because it meets a clinical case definition
(e.g., generalized rash accompanied by high fever and cough, coryza, or conjunc-
tivitis) or because a health-care professional suspects that an illness is a case of
measles.
• As measles incidence decreases, the surveillance system should acquire the ca-
pacity to assess risk for measles outbreaks based on the prevalence of measles
susceptibility as measured by serologic markers of immunity, surveys of vaccina-
tion coverage, or both. These data should allow health authorities to predict
outbreaks and to take action to prevent them.
• Monitoring of vaccination coverage achieved through routine activities or inten-
sive campaigns should be conducted at the lowest geopolitical level (e.g., district
or county) to identify local areas (e.g., villages or neighborhoods) or population
groups where children remain unvaccinated. In evaluating vaccination coverage,
countries using two-dose strategies should try to identify children who have re-
ceived two doses, one dose, or no doses. These data are helpful in developing
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mechanisms to rectify coverage shortcomings. The reported number of doses
administered at the second-dose opportunity may not equate with the number of
persons who actually received two doses because a first dose of vaccine may
be administered to some children who were not vaccinated at the first dose
opportunity.
• Monitoring the prevalence of susceptibility in a population may be useful for
planning supplementary vaccination campaigns. Case surveillance or sero-
surveillance data can help define age groups to be vaccinated in a catch-up or
follow-up campaign.
• As disease incidence decreases, mathematical modeling may be necessary to
obtain an accurate picture of the population prevalence of measles susceptibility.
Data required for such modeling can include vaccination coverage, age-specific
disease incidence, or prevalence of serologic markers of immunity from popula-
tion surveys.
• In contrast to polio surveillance, no single indicator of the sensitivity of a measles
surveillance system exists. PAHO has started using the proportion of reporting
sites that report at least one suspected measles case per year as a measure of
sensitivity. The European Regional Office of WHO has set a minimum level for
the laboratory investigation of suspected cases of one per 100,000 total popula-
tion per year. Other evaluations of sensitivity might include the proportion of
outbreaks for which the source is known. Further experience with each of these
approaches should be evaluated, and strategies should be adapted accordingly.
Laboratory Aspects
• In early stages of measles control, the function of the laboratory is to confirm
outbreaks of the disease. Subsequently, as disease incidence declines to very low
levels, laboratory confirmation of individual measles cases assumes increasing
importance. In countries that are attempting to eliminate measles, all isolated
cases of measles and at least one case from each chain of transmission should
be confirmed by laboratory tests. In a country or region that is attempting to
eliminate the disease, the occurrence of clinically confirmed cases (i.e., cases that
are not confirmed by laboratory tests or linked to laboratory-confirmed cases by
field epidemiologic investigation) should be regarded as a failure of the surveil-
lance system.
• A network of laboratories is a requirement for successful implementation of a
global measles elimination strategy. Such a network could be established by ex-
panding on the existing global poliovirus laboratory network. Specific functions
for national, regional, and reference laboratories should be established.
– National laboratories should be able to confirm the diagnosis of measles,
support measles virus isolation, provide quality assurance, and support epi-
demiologic surveys.
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– Regional laboratories should function as reference laboratories for serologic
diagnosis of measles and virus isolation. In addition, they should fulfill train-
ing and quality assurance functions and conduct research.
– Global reference laboratories should be responsible for quality control, profi-
ciency testing, technical advice, research, and maintaining a reference bank of
measles virus strains.
– The network also should have the capacity to perform laboratory diagnosis of
rubella and perhaps other rash illnesses that can be confused with measles.
• Laboratory tools are available to diagnose measles accurately by using EIA-IgM
assays. Laboratory tools also are available to characterize and track virus iso-
lates.
– The CDC antibody-capture IgM assay has been thoroughly evaluated and is
highly sensitive and specific. The CDC assay remains the reference test in the
Americas.
– Several commercial IgM assays are easier to perform than the CDC assay but
offer comparable sensitivity and specificity. A comprehensive evaluation of
these other assays is being performed.
– A radioimmunoassay (RIA) developed in the United Kingdom for detection of
measles IgM in oral fluids is highly sensitive and specific and may be useful in
countries capable of using RIA technology.
– Efforts have been undertaken to adapt the CDC antibody-capture EIA for use
with oral fluids. If successfully adapted, oral fluid specimens could be used to
confirm measles cases in laboratories that are not equipped to handle radio-
isotopes. The test would require a single specimen obtained at the time of the
patient’s first contact with the health-care system.
• Virologic surveillance, including isolation and genotyping of virus strains circu-
lating in a country or region, is an important tool for routine surveillance and for
evaluating progress toward measles elimination. Therefore, systematic efforts
should be undertaken promptly to collect specimens for viral genotyping and to
establish a global strain bank.
– As part of this effort, case investigations that include collection of specimens
for viral isolation should be undertaken in countries before they initiate elimi-
nation activities as a means of documenting patterns of virus circulation.
These data can be used to assess progress toward regional and global elimi-
nation of the disease.
– WHO should convene representatives of the laboratories performing measles
genome sequencing to develop guidelines for isolation and sequencing of
measles virus, as well as a standard system of nomenclature for measles
viruses.
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VACCINE SAFETY
Adverse events that occur after vaccination can be caused by the vaccine, occur
coincidentally (i.e., the events may be temporally but not causally related), or result
from programmatic errors. Adverse events caused by the vaccine include local and
systemic reactions, febrile convulsions, allergic reactions, and anaphylaxis. Adverse
events caused by programmatic errors include those resulting from unsafe injection
practices (e.g., abscesses at the injection site, toxic shock syndrome, septicemia, and
transmission of bloodborne viral infections, including hepatitis B or C and human
immunodeficiency virus [HIV]), and illness or injury caused by administration of
vaccine to persons for whom it is contraindicated. Unsafe injection practices can affect
the vaccine recipient, the person administering the vaccine (e.g., through needle stick
injuries), or other members of the community (e.g., because of improper disposal of
needles and syringes).
Immunization activities represent about 10% of the global total of injections admin-
istered each year. Approximately 800 million injections were administered in routine
EPI activities in the developing world in 1996, and another 240 million injections were
administered in emergency vaccination campaigns. If the world’s nations all adopt
measles elimination strategies, 1.6 billion children could receive a single additional
injection in measles catch-up vaccination campaigns and approximately 150 million
could receive follow-up injections each year. Most of these vaccinations are likely to
be administered by syringe because currently available jet injectors are not recom-
mended for use in mass vaccination campaigns. New jet injectors are under dev-
elopment and will be field tested beginning in 1998, but their cost and suitability for
use in developing countries are unknown.
The problems of using disposable needles and syringes for vaccination, whether
for routine vaccination or in mass catch-up campaigns, are appreciable. Equipment
shortages during mass campaigns or failure to dispose of used equipment after the
campaign can increase risks for reuse of disposable syringes. Autodestruct syringes,
by contrast, pose no risk for reuse during or after the campaign. Whether autodestruct
syringes or disposable syringes are used, collection and incineration of used syringes
and needles should be part of all mass vaccination campaigns.
Experience in the United Kingdom illustrates the importance of surveillance in
establishing the background incidence of adverse events and monitoring their occur-
rence during and after a catch-up vaccination campaign. During a 1-month period
in 1994, MR vaccine was administered to 92% of the United Kingdom’s 8.4 million
children aged 5–16 years. The surveillance system received 1,231 reports of 2,783 ad-
verse events; included were 709 serious reactions affecting 557 children. More than
half the reported events (e.g., allergic reactions, syncope, or convulsions) occurred
within 24 hours after vaccination. A total of 120 reports were received of immediate
allergic reactions or anaphylaxis. Approximately half of these children were referred
to hospitals but few were admitted overnight; all recovered fully. Adrenaline was ad-
ministered to fewer than half the children reported to have experienced anaphylaxis,
indicating that the reported events may not have been true anaphylactic reactions.
Investigation revealed that 24 of 29 reports of “convulsions” were episodes of syn-
cope. Rates of most adverse events, including arthritis and facial palsy, were lower
than background levels.
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Conclusions: Vaccine Safety
• Unless field personnel are well trained and supervised and provided with the
correct equipment, improper administration of injectable vaccines during mass
vaccination campaigns can cause bacterial infections (e.g., abscesses, toxic
shock syndrome, or septicemia) and transmit bloodborne diseases (e.g., hepati-
tis B, hepatitis C, HIV, syphilis, and malaria).
• Proper disposal of needles and syringes is an important component of routine
immunization programs and mass measles vaccination campaigns.
– Autodestruct syringes are the equipment of choice for mass vaccination cam-
paigns and the preferred type of disposable equipment for routine admin-
istration of vaccines.
– Puncture-resistant containers (“safety boxes”) are required for collecting and
disposing of used disposable and autodestruct syringes, needles, and other
injection materials to reduce the risk to health staff and the general public
from contaminated needles and syringes.
– Training health-care workers in safe injection practices should be part of the
planning and implementation of mass vaccination campaigns. Supervisors
and senior managers should stress safe injection practices during the vaccina-
tion campaign. Evaluation of vaccination campaigns should include measures
of observance of safe injection practices and disposal of used equipment.
– Donors should be encouraged to supply vaccines in a bundle consisting of
vaccine, autodestruct syringes, safety boxes, and training.
– The development of safe and cost-effective alternative technologies suitable
for administration of vaccines in mass immunization campaigns (e.g., a new
generation of jet injectors) should be encouraged.
• Surveillance for adverse events after vaccination is important both for routine
immunization programs and for mass immunization campaigns. Planning for
campaigns should include establishing a mechanism to investigate and respond
to reports of adverse events associated with administration of vaccines. At a
minimum, the surveillance mechanism should be able to detect deaths and se-
vere adverse events. Community-based surveillance systems can be used to
detect adverse events that occur after vaccination as well as cases of measles.
• The number or rate of adverse events reported during mass immunization cam-
paigns—whether vaccine-induced, coincidental, or caused by programmatic
errors—should approximate the number or rate expected after administration of
a similar number of vaccinations in routine immunization programs. The rate of
vaccine-induced events may be lower than expected because many of those vac-
cinated are already immune and therefore not at risk. After mass vaccination
campaigns, temporal clustering of adverse events apparently caused by the vac-
cine can cause substantial public concern. Knowledge of background rates of
specific types of adverse events (e.g., anaphylaxis, febrile seizures, abscess at the
injection site) can be very important in addressing public concern.
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RESEARCH
Presentations during the meeting addressed research in three areas relevant
to measles eradication: a) opportunities for research concerning measles immunol-
ogy, b) development of alternative routes for administration of measles vaccine, and
c) optimal age for measles vaccination. Measles virus and measles vaccinology offer
unique opportunities for research in several areas—molecular and basic research,
epidemiologic research, clinical disease and diagnostics, new vaccines, and new
routes of administration. Studies have begun to examine measles-induced immune
suppression, the pathogenesis of measles, alternative formulations and means of ad-
ministration of measles vaccines, correlates of vaccine-induced cellular and humoral
immunity, and the role of adjuvants in measles vaccines. Studies of immunocom-
promised persons infected with measles are particularly important because of the
increasing incidence and prevalence of HIV infection. Particularly relevant to control
and elimination of measles is research concerning persistent carriage of measles virus
by immunocompromised persons.
Findings of several studies indicate that aerosol administration of measles vaccine
is effective, particularly if Edmonston-Zagreb vaccine is used. Administering measles
vaccine by the aerosol route is rapid, might be less costly than single-use needles and
syringes, is nontraumatic, avoids risks for transmission of HIV and hepatitis B, and
does not require medically trained personnel. Aerosols are easy to administer to
school-aged children but are more difficult to administer to younger children and in-
fants. The apparatus for administration of aerosol vaccines has limitations; it is
cumbersome, requires crushed ice, and is not useful for single dose administration.
Questions remain about possible effects on vaccinators of repeated exposure to
aerosolized measles virus and potential adverse effects of aerosol vaccines, particu-
larly among persons infected with HIV.
Factors that affect the optimal age for administering the first dose of measles vac-
cine include the risk for measles among infants, vaccination coverage among young
children and infants, the prevalence in the target population of possible alterations in
immunity caused by acquired conditions (e.g., HIV infection), and vaccine effective-
ness, which is relatively low among infants because of maternally derived antibody
but increases as children grow older. Factors that affect the optimal age range for
inclusion in catch-up or follow-up measles vaccination activities include cost, the
prevalence of measles susceptibility among young adults, and ease of access to un-
vaccinated persons.
Conclusions: Research
• Research on measles and measles immunization in immunocompromised per-
sons should be conducted to clarify the potential for persistent carriage of
measles virus. Measles virus infection is an important model for immunosup-
pression in the human host. Research concerning the pathogenesis of measles
and immune responses of immunocompromised and immunologically normal
persons to wild measles virus and vaccine viruses should continue.
• Aerosol administration of measles vaccine to school-aged children may be useful
for catch-up campaigns but is less likely to be useful for routine vaccination of
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young children. Additional research is necessary to determine its feasibility in
field operations. Further research on alternative routes of vaccine administration
should be encouraged. However, because introduction of new vaccines requires
extensive testing and regulatory review, and because the safety and efficacy of
presently licensed vaccines are well established, the introduction of new vac-
cines is unlikely to affect the feasibility of measles elimination or eradication.
ECONOMIC IMPLICATIONS OF MEASLES ELIMINATION
An economic evaluation presented at the meeting compared several options for
future measles for a hypothetical western European country immunization policy, in-
cluding the baseline case of no change in vaccination policy. All other options saved
costs compared with the baseline. Optimal choices depended upon assumptions con-
cerning past success in measles vaccination. If 70% of children aged ≤2 years were
assumed to have been vaccinated, the optimal strategy would be to increase vaccina-
tion coverage with the first dose to ≥95%, adopt a two-dose vaccination policy, and
conduct mass vaccination campaigns among persons in age groups with susceptibil-
ity levels ≥5%. In contrast, if past coverage among children aged ≤2 years were
assumed to exceed 90%, increasing vaccination coverage with one dose of measles
vaccine, without the addition of a second dose, would save costs compared with no
change. In either situation, improving coverage with the first dose should be under-
taken before adopting a two-dose vaccination schedule.
Also presented at the meeting were findings of an economic assessment that con-
trasted various global measles prevention strategies—control, elimination, and
eradication. For each country, preliminary estimates were made of measles disease
burden, vaccine needs, required financial resources, relative importance of economic
and epidemiologic assumptions, and opportunity costs of investing in measles control
rather than other selected health interventions. For each country, an estimate of age-
specific measles susceptibility based on reported vaccination coverage, vaccine
efficacy, reported age-specific attack rates, and case-fatality ratios was constructed.
Costs of vaccination included direct vaccine and program costs, administration costs,
costs of adverse events, and costs to treat measles cases that are not prevented. A
3% discount rate was used to estimate future costs in 1997 United States dollars. Pre-
sent costs for vaccines, programs, and treatment of measles cases were estimated at
$480 million annually. Findings of the analysis indicate that 80% of measles control
program costs and disease treatment costs are paid by high-income countries (as
categorized by the World Bank). However, of every 100 persons added each year to the
global population that is susceptible to measles, 74 reside in low-income countries.
The World Bank categorizes the world’s most populous nations, India and China, as
low-income countries. Under the assumptions used in this preliminary analysis, eradi-
cation would be cost-effective. The additional costs for vaccine and vaccination
programs required to achieve eradication were estimated to be $4.7 billion, of which
only $0.7–$1.8 billion would be required for low income countries.
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Conclusions: Economic Implications of Measles Elimination
• Different approaches have been taken to assess the economic costs, benefits,
and cost-effectiveness of measles control, elimination, and eradication. These
analyses indicate that programs to control measles are highly cost-effective. Ad-
ditional programmatic investments to interrupt measles transmission are also
cost-effective and may be cost-saving in some countries.
• Greater agreement is needed concerning appropriate approaches to economic
analysis of measles eradication, including consideration of marginal and oppor-
tunity costs, is needed so that these estimates can be used to formulate policy
and estimate budgetary resources required to achieve eradication.
• Measles eradication presupposes a substantial investment in infrastructure (i.e.,
physical capital and surveillance and management systems) and “human capi-
tal” (i.e., training of primary health-care personnel, front-line supervisors, and
development of management resources). Benefits of the investment will include
a) elimination of illness and death caused by measles virus, b) elimination of the
recurring costs and risks associated with measles immunization, and c) a perma-
nent contribution to development of primary health services in developing
countries. Proper management of the investment requires specific and inten-
tional efforts to maximize the benefits that can accrue to the overall health
system from eradication efforts. Specific benchmarks should be developed to
monitor interaction of eradication efforts and primary health-care development.
NEXT STEPS
Several lessons have been learned from previous efforts to eradicate communica-
ble diseases (5 ). To eradicate a disease, medical scientists must have a thorough
understanding of its natural history. To achieve consensus concerning the appropriate
approach to eradication and sustained political commitment of resources, proponents
of eradication should consult widely before embarking on the effort. National and in-
ternational surveillance should be implemented early in the disease eradication
program, and surveillance information should be used to guide program strategy. Im-
plementation of the eradication strategy should emphasize flexibility and adaptation
to the social, political, and public health circumstances of each country. A specific
target date for eradication should be set to focus global efforts and maintain commit-
ment to the goal of eradication.
In addition to these general considerations, factors to be considered in implement-
ing measles eradication include the high short-term costs of the endeavor, the risk of
failure (i.e., the probability of failure and the potential consequences of failure), and
the need to strengthen comprehensive health services to achieve eradication. Among
the factors that favor measles eradication are 
• the perceived importance of the disease in less developed countries; 
• the availability of highly effective vaccines and vaccination strategies; 
• the likely favorable benefit:cost ratio;
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• rapid communications developed over the last two decades; and
• the capabilities and know-how that are the legacy of smallpox and polio eradica-
tion efforts.
Factors that do not favor eradication include
• the high infectiousness of measles; 
• increasing worldwide population density and urbanization (particularly in devel-
oping countries); 
• increasing international travel;
• logistics questions, including the use of needles and syringes; and 
• the potential competition for resources with other ongoing eradication efforts
(i.e., efforts to eradicate polio and Guinea worm).
In discussions of next steps, speakers urged meeting participants to
• capitalize on lessons learned in previous global disease eradication campaigns,
particularly the successful campaign to eradicate smallpox and lessons currently
being learned in polio eradication activities; 
• use surveillance information from ongoing measles control and elimination
efforts to refine national and regional disease control strategies;
• discuss measles elimination at future international meetings on polio
eradication;
• continue to increase routine measles vaccination coverage; 
• use NIDs for measles as well as polio in countries where such efforts are feasible;
and 
• accelerate efforts to control measles virus in urban populations.
The next steps for measles control and elimination activities include design of a
global strategy, preparing an operational plan and budget, obtaining political support,
developing a partner/donor coalition, and implementing the strategy. Each step
requires action at national, regional, and global levels. In addition, a consensus must
be developed concerning the timing of measles elimination in relation to polio eradi-
cation. Specifically, should measles elimination be undertaken simultaneously with
efforts to eradicate polio? Or should the efforts be undertaken sequentially? Meeting
participants suggested that measles elimination should not be undertaken at the
national level before poliovirus transmission is interrupted. At the global level, in con-
trast, activities aimed at achieving measles eradication should begin before polio
eradication is achieved. Polio eradication must remain the first priority.
Meeting participants pointed out that the more rapidly measles elimination activi-
ties proceed at the national and regional levels, the more easily measles eradication
will be accomplished. Conversely, the more slowly elimination activities proceed,
the more difficult eradication will be. Once measles transmission is interrupted in a
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population, risks for virus importation and reestablishment of transmission increase
over time. Conducting repeated follow-up vaccination campaigns is operationally dif-
ficult and expensive. Because routine vaccination and follow-up campaigns rarely
succeed in vaccinating all susceptible persons in a population, and because the vac-
cine is not 100% effective, the prevalence of measles susceptibility in the population
tends to increase over time. Thus, the more protracted the global measles eradication
campaign, the greater the risk for reestablishment of measles in countries where
transmission of the virus has been interrupted.
Participants also considered funding of measles eradication. Projects that attract
donor support are successful (or have a high probability of success), are both politi-
cally and socially popular, provide visibility and recognition for donors, and have a
specific goal and target date for completion. To attract support from potential partners
and donors among governments, nongovernmental organizations, and the private
sector, advocates of measles eradication should develop consensus concerning their
objectives and strategies and communicate these objectives simply and directly. To
succeed, advocates of eradication must reach consensus concerning the global dis-
ease burden of measles, likely cost savings from eradicating the disease, and
resources required from external sources to accomplish the goal. The advocacy strat-
egy should include identifying the key messages concerning measles eradication,
forming coalitions of partners (including those in the private sector), and identifying
advocates for fund-raising. Meeting participants considered consistency in messages
about each aspect of measles eradication essential to the success of the advocacy
strategy.
Conclusions: Next Steps
• Substantial progress has been made in controlling measles. Measles trans-
mission has been interrupted in several countries, reinforcing the view that mea-
sles eradication is technically feasible using existing vaccines and intervention
strategies.
• Three of the six WHO regions have established or are considering target dates for
elimination of measles, indicating that the goal of eradication is likely to be
adopted in the next 3–5 years.
• Although measles elimination has already begun in many areas, global eradica-
tion poses several additional challenges. Elimination activities must be inte-
grated with development of the primary health-care system because that system
will be crucial for maintenance of progress. Because they have few primary
health-care resources, high measles incidence, and a substantial burden of infec-
tion with HIV, the countries of Africa are expected to present the greatest
challenges to measles elimination. The most effective measles control strategies
for these countries, which also contribute to strengthening their health-care sys-
tems, should be undertaken early in the process of eradication; the goal should
be to demonstrate that measles transmission can be interrupted despite the sub-
stantial barriers to success that exist in Africa.
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• Although perhaps not essential for interruption of measles virus transmission,
effective routine immunization services facilitate achieving and maintaining
measles elimination in a country or region.
• A renewed commitment to the goal of polio eradication is imperative, because
much remains to be done to eradicate polio, particularly in the Indian sub-
continent and Africa. Success in polio eradication will facilitate progress in
measles elimination. Properly implemented, polio eradication and measles
elimination activities can be mutually reinforcing and represent a natural joining
of efforts. However, conjoining the efforts must not divert attention or resources
from progress toward polio eradication. From a global perspective, measles
eradication appropriately follows and builds on polio eradication activities.
Nonetheless, planning for regional control, elimination, and ultimate eradication
of measles should commence before polio eradication has been completed.
• Individual nations can and should accelerate measles control and, if high popula-
tion immunity is achieved, can interrupt measles virus transmission. However,
elimination of measles requires coordinated regional (i.e., multinational) efforts,
and eradication requires coordinated global efforts. Sustaining interruption of
measles transmission is difficult and expensive. Consequently, as the area from
which measles has been eliminated increases, setting a goal of eradication and
achieving it in a short period will become increasingly important.
• Estimates of additional resource commitments needed to achieve measles eradi-
cation should be developed using the best available information. These
estimates should be used to develop partnerships and marshal support for eradi-
cation of the disease.
• Achieving measles eradication will require close and effective partnerships
among official agencies, private and voluntary sectors, and external donors.
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